AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUN 224 min read$GRDN

Guardian Pharmacy Services, Inc. (GRDN): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Guardian Pharmacy Services, Inc. (GRDN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001802255 0001802255 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22,

Original reporting
SEC EDGAR 8-K
Published Jun 22, 2026, 8:35 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 22, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$GRDN
Neutral
medium confidence
Mentioned
$GRDN
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$GRDNNeutralLow
01

Why it matters

The main market-relevant element is the CFO succession (David Morris to COO; Will Mudd to CFO) and a short transition period for Forbes (July 1–Aug 31).

02

Market read

Provides a concrete management transition timeline that can influence investor perception of financial reporting continuity, but includes no new financial guidance.

03

What to watch

Watch for follow-on disclosures (e.g., updated credit/financing terms, internal control commentary, or changes to compensation/targets) around the July 1 effective date; this 8-K alone doesn’t quantify impact.

Relevance 6/10Novelty 5/10Timing: effective July 1, 2026 (CFO/COO transition)

Background

The company filed an SEC Form 8-K (Item 5.02) announcing retirement of EVP Sales & Operations Kendall Forbes and officer transitions effective July 1, 2026.

Company-level read

Ticker impact

$GRDNNeutralMedium confidence
Context

Guardian Pharmacy Services disclosed executive transitions: CFO David Morris moves to COO and Will Mudd becomes CFO effective July 1, 2026.

Expected impact

Likely limited, with any move driven by sentiment around management continuity rather than new fundamentals.

Evidence & confidence

The filing is an SEC 8-K Item 5.02 describing retirements and officer appointments with effective dates, but it contains no earnings, guidance, or operational performance datapoints.

Market effects

Sector

Minimal sector read-through; this is company-specific management change within a PBM/pharmacy services operator.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The CFO change could be a precursor to broader operational or financial strategy shifts not disclosed in this 8-K, so the market may re-rate if subsequent filings reveal changes in guidance or accounting priorities.

Key entities

  • issuer
    Guardian Pharmacy Services, Inc.

    Subject of the 8-K; announced executive retirements and officer appointments effective July 1, 2026.

  • executive
    David Morris

    Moves from EVP & CFO to EVP & COO effective July 1, 2026; also a board member since 2021.

  • executive
    Will Mudd

    Appointed Senior Vice President & CFO effective July 1, 2026; previously SVP Finance since 2012.

  • executive
    Kendall Forbes

    Retires from all positions effective July 1, 2026; continues as employee July 1–Aug 31 for transition support.

Read at source← All news

Related articles

AUG 8
$GRDNMed

Guardian Pharmacy Services Q2 Earnings Call Highlights

Guardian Pharmacy Services (GRDN) reported Q2 net income of $22.1M vs $8.8M a year earlier, including an $8.5M payer-dispute settlement recorded as other income. The company expects H2 revenue to fall low-single digits YoY due to IRA pricing reductions, with adjusted EBITDA margin stable in Q3 and seasonally higher in Q4. It also appointed Morris as COO and named a new CFO.

yahoo.com5 min
AUG 7
$GRDNMedAI 8/10

Guardian Pharmacy: Q2 Earnings Snapshot

Guardian Pharmacy Services Inc. (GRDN) reported Q2 profit of $21.9 million, or 34 cents per share. Adjusted earnings were 29 cents versus a Zacks-surveyed analyst average of 26 cents. Revenue was $351.8 million. The company forecast full-year revenue of $1.43 billion to $1.45 billion.

local3news.com2 min
AUG 6
$GRDNHigh

Guardian Pharmacy Services, Inc. (GRDN): Results of Operations and Financial Condition

Guardian Pharmacy Services, Inc. (GRDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d160709dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Guardian Pharmacy Services Reports Second Quarter 2026 Financial Results; Raises Full-Year Guidance ATLANTA, August 6, 2026 – Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation’s leading long-term care (“LTC”)

SEC EDGAR 8-K4 min
AUG 8
$000660.KSMed

SK Hynix said to mull options for US$3 billion Chongqing plant

SK Hynix is considering options for its Chongqing, China semiconductor packaging and testing facility, including possibly bringing in an investor to accelerate growth. People familiar said a potential stake sale could value the plant at about US$3 billion and SK Hynix may keep a minority stake. Separately, it plans a 54 trillion won (US$38 billion) South Korea expansion for DRAM and NAND.

businesstimes.com.sg3 min